2 results
Approved WMOCompleted
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
Approved WMOCompleted
(1) To asses the influence of P-gp function at the BBB on flumazenil binding to the GABAA-receptor in pharmacoresistant patients with temporal lobe epilepsy (TLE), using PET and [11C]flumazenil as a ligand and tariquidar as P-gp blocker. (2) If we…